RDY Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

84.67B

+1.29%

18.311

+15.71%

Estimates Revision

The market is revising Downward the revenue expectations for Dr. Reddy's Laboratories Limited (RDY) for FY2026, with the revenue forecasts being adjusted by -0.57% over the past three months. During the same period, the stock price has changed by -6.56%.

Revenue Estimates for FY2026

Revise Downward

-0.57%

In Past 3 Month

EPS Estimates for FY2026

Revise Downward

-3.64%

In Past 3 Month

Stock Price

Go Down

-6.56%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Dr Reddy's Laboratories Ltd (RDY.N) is 21.52, compared to its 5-year average forward P/E of 20.30. For a more detailed relative valuation and DCF analysis to assess Dr Reddy's Laboratories Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

20.30

Current PE

21.52

Overvalued PE

24.29

Undervalued PE

16.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

12.45

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

14.67

Undervalued EV/EBITDA

10.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3.20

Current PS

0.00

Overvalued PS

3.55

Undervalued PS

2.84

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

RDY News & Events

Events Timeline

No data

News

6.5

01-01Yahoo Finance

ReadyTech Holdings: 54% Shares Controlled by Top 4 Shareholders

6.5

2025-12-09NASDAQ.COM

Zacks Industry Outlook Spotlights Sandoz, Teva Pharmaceuticals, and Dr. Reddy's

7.5

2025-12-08Newsfilter

Immutep Secures Exclusive Eftilagimod Alfa Licensing Deal with Dr. Reddy's for $20M Upfront Payment

People Also Watch

Frequently Asked Questions

What is Dr Reddy's Laboratories Ltd (RDY) stock price today?

The current price of RDY is 13.4 USD — it has increased 0.37 % in the last trading day.

What is Dr Reddy's Laboratories Ltd (RDY)'s business?

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

What is the price predicton of RDY Stock?

Wall Street analysts forecast RDY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RDY is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Dr Reddy's Laboratories Ltd (RDY)'s revenue for the last quarter?

Dr Reddy's Laboratories Ltd revenue for the last quarter amounts to 1.01B USD, increased 5.41 % YoY.

What is Dr Reddy's Laboratories Ltd (RDY)'s earnings per share (EPS) for the last quarter?

Dr Reddy's Laboratories Ltd. EPS for the last quarter amounts to 0.20 USD, increased 11.11 % YoY.

What changes have occurred in the market's expectations for Dr Reddy's Laboratories Ltd (RDY)'s fundamentals?

How many employees does Dr Reddy's Laboratories Ltd (RDY). have?

Dr Reddy's Laboratories Ltd (RDY) has 27811 emplpoyees as of January 10 2026.

What is Dr Reddy's Laboratories Ltd (RDY) market cap?

Today RDY has the market capitalization of 11.16B USD.